Inhibikase Therapeutics Inc. (IKT): Price and Financial Metrics

Inhibikase Therapeutics Inc. (IKT): $2.14

0.02 (-0.93%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

C

Add IKT to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#136 of 360

in industry

IKT Price/Volume Stats

Current price $2.14 52-week high $5.61
Prev. close $2.16 52-week low $0.79
Day low $2.07 Volume 54,414
Day high $2.22 Avg. volume 190,362
50-day MA $2.04 Dividend yield N/A
200-day MA $2.12 Market Cap 13.21M

IKT Stock Price Chart Interactive Chart >

IKT Stock Summary

  • IKT has a higher market value than just 4.25% of US stocks; more precisely, its current market capitalization is $8,150,050.
  • Revenue growth over the past 12 months for INHIBIKASE THERAPEUTICS INC comes in at 424.23%, a number that bests 98.56% of the US stocks we're tracking.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for IKT comes in at -104.82% -- higher than that of just 4.02% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to INHIBIKASE THERAPEUTICS INC, a group of peers worth examining would be GWH, MRKR, DRRX, HYLN, and GSIT.
  • Visit IKT's SEC page to see the company's official filings. To visit the company's web site, go to www.inhibikase.com.

IKT Valuation Summary

  • IKT's price/earnings ratio is -0.4; this is 101.37% lower than that of the median Healthcare stock.
  • Over the past 37 months, IKT's price/sales ratio has gone down 60.6.

Below are key valuation metrics over time for IKT.

Stock Date P/S P/B P/E EV/EBIT
IKT 2023-12-29 24.1 0.5 -0.4 0.3
IKT 2023-12-28 23.1 0.5 -0.4 0.4
IKT 2023-12-27 22.2 0.5 -0.4 0.4
IKT 2023-12-26 23.5 0.5 -0.4 0.4
IKT 2023-12-22 25.6 0.6 -0.4 0.3
IKT 2023-12-21 24.1 0.5 -0.4 0.3

IKT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • IKT has a Quality Grade of C, ranking ahead of 43.42% of graded US stocks.
  • IKT's asset turnover comes in at 0.094 -- ranking 267th of 681 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows IKT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2020-12-31 0.094 1 0.758

IKT Price Target

For more insight on analysts targets of IKT, see our IKT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $13.50 Average Broker Recommendation 1.5 (Moderate Buy)

Inhibikase Therapeutics Inc. (IKT) Company Bio


Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease, and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a c-Abl protein kinase inhibitor for use in the treatment of Parkinson's Disease, dysphagia, and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. Its research phase products comprise IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body; and IkT-148x series of portfolio compounds for use in the treatment of Dementia with Lewy Body and Multiple System Atrophy. The company was founded in 2008 and is headquartered in Atlanta, Georgia.


IKT Latest News Stream


Event/Time News Detail
Loading, please wait...

IKT Latest Social Stream


Loading social stream, please wait...

View Full IKT Social Stream

Latest IKT News From Around the Web

Below are the latest news stories about INHIBIKASE THERAPEUTICS INC that investors may wish to consider to help them evaluate IKT as an investment opportunity.

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

BOSTON and ATLANTA, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today issued a Letter to Shareholders. Dear Fellow Shareholders of Inhibikase Therapeutics: What a ride it has been in 2023. The year began with a quick r

Yahoo | December 19, 2023

Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro

- Pre-NDA Meeting to discuss requirements for a 505(b)(2) NDA submission for IkT-001Pro in up to eight blood and stomach cancer indications - - Bioequivalence to 400 mg and 600 mg imatinib mesylate completed with minimal adverse events - BOSTON and ATLANTA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, P

Yahoo | December 4, 2023

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity

Company to host conference call on Wednesday, November 15, 2023 at 8:00 a.m. ETBOSTON and ATLANTA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today reported financial results for the third quarter ended September 30,

Yahoo | November 14, 2023

Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023

This release corrects and replaces the headline in the release that was disseminated on November 7, 2023. The reason for this correction is to fix the title which previously stated, "second quarter" rather than "third quarter." BOSTON and ATLANTA, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's

Yahoo | November 7, 2023

Inhibikase Therapeutics to Report Second Quarter Financial Results on November 14, 2023

BOSTON and ATLANTA, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that it will report financial results for the third quarter ended September 30, 2023, on Tuesday, November 14, 2023, after the close of U.S.

Yahoo | November 7, 2023

Read More 'IKT' Stories Here

IKT Price Returns

1-mo -29.03%
3-mo 131.55%
6-mo 8.63%
1-year -50.46%
3-year -94.68%
5-year N/A
YTD 68.50%
2023 -57.67%
2022 -65.99%
2021 -78.70%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!